10 Best Major Stocks to Buy According to Wall Street Analysts

7. AbbVie Inc. (NYSE:ABBV)

Based on a report released on April 10, RBC Capital analyst Trung Huynh maintained a Buy rating on AbbVie Inc. (NYSE:ABBV) while also keeping the firm’s price target of $260. The firm’s price target is slightly higher than the median Wall Street analysts’ price target of $259.

As CBS News reported on April 7, AbbVie Inc. (NYSE:ABBV) and Roche, through their Genentech Unit, have joined TrumpRx. TrumpRx is a government-run platform that sells medicines directly to consumers at discounted prices. With this move, they become the 10th and 11th drug makers on the platform. AbbVie Inc. (NYSE:ABBV) will provide its arthritis drug Humira at an 86% discount under a pricing agreement with the U.S. government. Genentech has also agreed to sell its flu drug Xofluza for $50, significantly lower than its usual price of $168. The total number of medicines available on TrumpRx has increased to 61, up from about 40 when the platform launched earlier this year.

According to CNN’s compilation, AbbVie Inc. (NYSE:ABBV) is currently covered by 33 Wall Street analysts and has a consensus Buy rating. Analyst estimates suggest the stock could rise as high as $328, implying more than 58% upside from current levels.

AbbVie Inc. (NYSE:ABBV) operates as a biopharmaceutical company. It is involved in the development, commercialization, manufacturing, and sale of medicines and therapies. The company provides Skyrizi, Rinvoq, Imbruvica, Elahere, Venclexta, Epkinly, and Emrelis.